RSS-Feed abonnieren

DOI: 10.1055/a-2642-7488
Assessing the Significance of Hyperthermia in Newborns Undergoing Phototherapy for Hyperbilirubinemia
Abstract
Objective
About 2% of full-term neonates are evaluated for fever, with serious bacterial infections (SBIs) identified in roughly 10% of cases. The 2021 American Academy of Pediatrics guideline standardizes febrile neonate evaluation, but factors like phototherapy for hyperbilirubinemia can complicate decisions. Phototherapy-associated hyperthermia raises concern about distinguishing environmental causes from true infection. This study assessed the prevalence of hyperthermia in neonates receiving phototherapy and its association with SBI.
Study Design
We performed a retrospective chart review of neonates admitted for phototherapy at a quaternary pediatric hospital (2019–2022). Using International Classification of Diseases codes, we identified patients with hyperthermia (≥38°C) and reviewed whether they underwent SBI evaluation and follow-up within 2 weeks.
Results
Among 639 neonates, 9 (1.4%) developed hyperthermia. Two (22%) were diagnosed with an SBI; one had a negative SBI workup, and six were not further evaluated. None of the seven without SBI returned for care. The 1.4% hyperthermia rate is not higher than the general neonatal fever prevalence (2%).
Conclusion
Hyperthermia during phototherapy is uncommon, but the 22% SBI rate in febrile neonates is noteworthy. Elevated temperatures in this context should not be presumed to be environmental. Clinicians should maintain vigilance and consider full SBI evaluations.
Key Points
-
Consider SBIs in febrile neonates on phototherapy; do not attribute fever to environmental factors.
-
Phototherapy rarely causes fever; while it warms infants, it does not raise fever risk.
-
Standardized approaches reduce variability in fever care.
Keywords
neonate - fever - phototherapy - hyperbilirubinemia - serious bacterial infection - hyperthermia evaluationApproximately 2% of full-term neonates are evaluated for fever in the neonatal period, with variable approaches in the evaluation and care of these patients.[1] [2] Of these patients, the prevalence of life-threatening serious bacterial infections (SBIs) has remained approximately 10% for more than 30 years.[1] Though the 2021 American Academy of Pediatrics Clinical Practice Guideline for the evaluation and treatment of well-appearing febrile neonates provides a means of decreasing practice variability, confounding factors that cause hyperthermia can lead to inconsistencies in management.
One potential confounding factor is phototherapy for neonatal hyperbilirubinemia. Given the nuances of isolette temperature regulation and perception of the phototherapy/isolette environment leading to higher temperatures, some providers question whether hyperthermia during phototherapy is due to environmental factors or underlying infection. This adds variability in the evaluation and management of patients who have a fever while undergoing phototherapy. Our study aimed to assess the prevalence of hyperthermia in neonates undergoing phototherapy for hyperbilirubinemia and the significance of hyperthermia as it relates to SBI in this population.
Methods
Through retrospective chart review at a single, quaternary care pediatric institution, we extracted temperature measurements from the electronic medical records (EMRs) of neonates admitted to acute care units for hyperbilirubinemia requiring phototherapy over a 4-year period from 2019 to 2022. Detailed chart review of neonates with temperature ≥38°C revealed when further evaluation was conducted and the outcomes of any such evaluation. From these data, we calculated the prevalence of hyperthermia in neonates who were undergoing phototherapy and the prevalence of SBI in this population. Patients of interest for the study were identified using relevant International Classification of Diseases (ICD) codes for hyperbilirubinemia requiring phototherapy. Chart review included data gathered for that admission as well as a review for possible readmissions over the subsequent 2 weeks to capture any patients that may have had SBI during this time. The study was approved by our Institutional Review Board.
Results
During the study period, 639 infants were admitted to an acute care bed with the diagnosis of hyperbilirubinemia requiring phototherapy. Nine (1.4%) of these infants had recorded temperatures ≥38°C. Of these, two (22%) had an SBI. For the other seven febrile patients, one underwent evaluation for a potential SBI, which was negative. None returned for care within 2 weeks following discharge. Details of these patients are seen in [Table 1] and [Fig. 1].


Discussion
In our cohort, the prevalence of hyperthermia in patients undergoing phototherapy was 1.4% and relatively low. Compared with the previously reported 2% suggesting no increased risk for hyperthermia when undergoing phototherapy. Most noteworthy, in our study, the prevalence of SBI in febrile neonates (22%) receiving phototherapy exceeded that of the general febrile neonate population published previously.[1]
Given similar or even lower rates of fever in neonates undergoing phototherapy, and higher prevalence of SBI we observed in our data, we believe that the environmental impacts of phototherapy should not be used as an explanation for hyperthermia in this patient population and that these patients should undergo further SBI evaluation.
Limitations of our study include only a single center and a relatively small sample size. Our patient data was pulled using ICD codes for hyperbilirubinemia requiring phototherapy, but may be impacted by variabilities in primary diagnosis codes, possibly leading to patients not being included in our data. Additionally, it is possible that patients treated within our system for hyperbilirubinemia may have been admitted with an SBI to another facility and, therefore, not accessible in our EMR.
Many guidelines for the evaluation and management of hyperthermia in neonates include hyperbilirubinemia as a risk factor for underlying sepsis. Therefore, the presence of hyperthermia and hyperbilirubinemia deserves further evaluation for an underlying infectious etiology.
Conflict of Interest
None declared.
-
References
- 1 Greenhow TL, Hung YY, Pantell RH. Management and outcomes of previously healthy, full-term, febrile infants ages 7 to 90 days. Pediatrics 2016; 138 (06) e20160270
- 2 Burstein B, Anderson G, Yannopoulos A. Prevalence of serious bacterial infections among febrile infants 90 days or younger in a Canadian urban pediatric emergency department during the COVID-19 pandemic. JAMA Netw Open 2021; 4 (07) e2116919
Address for correspondence
Publikationsverlauf
Eingereicht: 27. Februar 2025
Angenommen: 19. Juni 2025
Artikel online veröffentlicht:
11. Juli 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Greenhow TL, Hung YY, Pantell RH. Management and outcomes of previously healthy, full-term, febrile infants ages 7 to 90 days. Pediatrics 2016; 138 (06) e20160270
- 2 Burstein B, Anderson G, Yannopoulos A. Prevalence of serious bacterial infections among febrile infants 90 days or younger in a Canadian urban pediatric emergency department during the COVID-19 pandemic. JAMA Netw Open 2021; 4 (07) e2116919

